Serial analysis of CTCs may provide biomarker predictive of NSCLC response to crizotinib
Serial analysis of CTCs may provide biomarker predictive of NSCLC response to crizotinib
http://bit.ly/2pN8f7U
Among patients with non-small cell lung cancer (NSCLC) fueled by ALK gene alterations who were being treated with crizotinib (Xalkori), a decrease in the number of circulating tumor cells (CTCs) harboring increased copies of the ALK gene over the first two months of treatment was associated with increased progression-free survival.
Singularity
via http://bit.ly/2pNoqCk
April 30, 2017 at 04:25PM
http://bit.ly/2pN8f7U
Among patients with non-small cell lung cancer (NSCLC) fueled by ALK gene alterations who were being treated with crizotinib (Xalkori), a decrease in the number of circulating tumor cells (CTCs) harboring increased copies of the ALK gene over the first two months of treatment was associated with increased progression-free survival.
Singularity
via http://bit.ly/2pNoqCk
April 30, 2017 at 04:25PM
Comments
Post a Comment